Trial · NCT00585039
Albuterol Versus Xopenex in Treatment of Acute Asthma in the Emergency Department (ED)
NCT00585039, Phase 4, Completed, Phoenix Children's Hospital; results first posted 2011-08-16
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Albuterol Versus Xopenex in Treatment of Acute Asthma in the Emergency Department (ED). Trials, record NCT00585039. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00585039
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Albuterol Versus Xopenex in Treatment of Acute Asthma in the Emergency Department (ED)
- NCT number
- NCT00585039
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 101 participants, actual
- Lead sponsor
- Phoenix Children's Hospital
- Conditions
- Asthma
- Interventions
- xopenex
- First posted
- 2008-01-02
- Last updated
- 2026-02-10
- Results first posted
- 2011-08-16
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Forced Expiratory Volume in 1 Sec (FEV1) Measured in L/Sec | Baseline and 4 hours | |
| Secondary | Clinical Asthma Score (CAS) | 4 hours | Change in clinical asthma score while in ED. 15 point clinical asthma score. Score ranges from 5 (no to mild respiratory distress) to a maximum of 15 (severe respiratory distress). |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Forced Expiratory Volume in 1 Sec (FEV1) Measured in L/Sec | Baseline and 4 hours | Enrollment period ended prior to final goal sample size. ITT. | L/sec | MEAN |
| SECONDARY | Clinical Asthma Score (CAS) | 4 hours | analysis per protocol | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Forced Expiratory Volume in 1 Sec (FEV1) Measured in L/Sec | Levalbuterol (Xopenex) | 19.8 | 95% Confidence Interval 14.4 to 67 | L/sec | |
| Change in Forced Expiratory Volume in 1 Sec (FEV1) Measured in L/Sec | Albuterol | 55.2 | 95% Confidence Interval 28 to 75.7 | L/sec | |
| Clinical Asthma Score (CAS) | Levalbuterol | 1.7 | 95% Confidence Interval 0 to 2.9 | units on a scale | |
| Clinical Asthma Score (CAS) | Albuterol | 3.0 | 95% Confidence Interval 1.2 to 3.9 | units on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Levalbuterol (Xopenex) | 57 | |
| Overall Study | STARTED | Albuterol | 44 | |
| Overall Study | COMPLETED | Levalbuterol (Xopenex) | 55 | |
| Overall Study | COMPLETED | Albuterol | 44 | |
| Overall Study | NOT COMPLETED | Levalbuterol (Xopenex) | 2 | |
| Overall Study | NOT COMPLETED | Albuterol | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Levalbuterol (Xopenex) | ||
| Total, all-cause mortality | Albuterol | ||
| Total, other adverse events | Levalbuterol (Xopenex) | 0 | 55 |
| Total, other adverse events | Albuterol | 0 | 44 |
| Total, serious adverse events | Levalbuterol (Xopenex) | 0 | 57 |
| Total, serious adverse events | Albuterol | 0 | 44 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Levalbuterol (Xopenex) vs Albuterol: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00585039
GET https://conductscience.org/api/trials/v1/NCT00585039/registered